Trump Deals with Lilly, Novo Nordisk Broadens Obesity Drug Access
- Here's a breakdown of the key takeaways from the article, focusing on the changes to GLP-1 (like Wegovy and Zepbound) coverage:
- * Government Agreements with Drugmakers: The US government (Trump governance) has reached agreements with Eli Lilly and Novo Nordisk to lower the cost of GLP-1 drugs for Medicare...
- In essence, this is a significant step towards making these potentially life-changing medications more accessible to a wider range of Americans, particularly those on Medicare.
Here’s a breakdown of the key takeaways from the article, focusing on the changes to GLP-1 (like Wegovy and Zepbound) coverage:
Key Points:
* Government Agreements with Drugmakers: The US government (Trump governance) has reached agreements with Eli Lilly and Novo Nordisk to lower the cost of GLP-1 drugs for Medicare and Medicaid.
* Price Reduction: The price paid by medicare and Medicaid will be capped at $245 per month.
* Medicare Copay: Eligible Medicare patients will pay a $50 monthly copay for GLP-1s, regardless of whether they’re using the drug for diabetes, obesity, or cardiovascular benefits.
* Medicare Coverage Timeline:
* Spring 2026: initial voluntary pilot program for Medicare part D plans. Most plans are expected to participate.
* 2027: The program becomes mandatory for all Medicare Part D plans.
* Eligibility for Medicare Coverage (Obesity/Cardiovascular Benefits):
* BMI of 27+ with prediabetes or cardiovascular disease.
* BMI of 30+ with related health conditions.
* BMI of 35+.
* Potential for Broader Insurance Coverage: Experts believe expanded Medicare coverage will likely lead to more commercial (private) insurance plans covering GLP-1s.
* Direct-to-Consumer Discount: Treatments will also be available at a discount through TrumpRx.gov for those with limited or no insurance.Monthly out-of-pocket costs could range from $50-$350.
* Current Barriers: High list prices ($1,000+/month) have limited access to these drugs due to spotty insurance coverage.
* Market Size: Approximately 8-9 million Americans currently use GLP-1s. The Medicare deal could perhaps add 40 million eligible patients.
* Legal Hurdle: A law currently prohibits Medicare from covering weight loss drugs, necessitating the pilot program approach.
In essence, this is a significant step towards making these potentially life-changing medications more accessible to a wider range of Americans, particularly those on Medicare. However, there are still eligibility requirements and questions about long-term coverage for patients who achieve weight loss.